Shots:

• The P-I study will evaluate the safety and immunogenicity of the vaccine as well as confirm dose selection in ~144 healthy subjects aged 18-55 and >55 yrs. As part of the two-dose cohort design- subjects will receive two injections (prime-boost)- 21 days apart  BNT162b1 vs PBO
• The dose range was determined based on early data from clinical trials conducted in Germany and the US. The participants will be dosed in Taizhou clinical P-I center- Jiangsu province
• BioNTech will provide the clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in EU while Fosun Pharma will exclusively commercialize the vaccine in Mainland China- Hong Kong- and Macau Special Administration Regions and in Taiwan if received approval in China

­ Ref: GlobeNewswire | Image: PharmaShots

Related News: Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19